Amphastar Pharmaceuticals (AMPH) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $78.7 million.
- Amphastar Pharmaceuticals' Operating Expenses rose 6679.24% to $78.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.5 million, marking a year-over-year increase of 2313.26%. This contributed to the annual value of $168.4 million for FY2024, which is 927.89% up from last year.
- Amphastar Pharmaceuticals' Operating Expenses amounted to $78.7 million in Q3 2025, which was up 6679.24% from $44.3 million recorded in Q2 2025.
- Amphastar Pharmaceuticals' 5-year Operating Expenses high stood at $78.7 million for Q3 2025, and its period low was $26.4 million during Q3 2021.
- Moreover, its 5-year median value for Operating Expenses was $38.5 million (2022), whereas its average is $40.4 million.
- As far as peak fluctuations go, Amphastar Pharmaceuticals' Operating Expenses tumbled by 1993.57% in 2021, and later surged by 6679.24% in 2025.
- Over the past 5 years, Amphastar Pharmaceuticals' Operating Expenses (Quarter) stood at $32.0 million in 2021, then rose by 4.23% to $33.3 million in 2022, then rose by 26.47% to $42.2 million in 2023, then decreased by 1.56% to $41.5 million in 2024, then skyrocketed by 89.61% to $78.7 million in 2025.
- Its Operating Expenses was $78.7 million in Q3 2025, compared to $44.3 million in Q2 2025 and $48.0 million in Q1 2025.